Healthcare Services

Global 5-Alpha Reductase Deficiency Market to Hit $2.35B by 2030 at 9.5% CAGR

April 16, 2026April 17, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The 5-Alpha Reductase Deficiency Market From 2026 To 2030?

The market size for 5-alpha reductase deficiency has demonstrated strong growth over recent years. It is projected to increase from $1.5 billion in 2025 to $1.64 billion in 2026, with a compound annual growth rate (CAGR) of 9.6%. The expansion observed during the historic period stems from factors such as limited public knowledge of rare genetic disorders, a reliance on clinical assessment for diagnostic methods, the incremental adoption of hormone testing, a rise in hospital-based treatment, and the slow progression in establishing specialized surgical procedures.

The market size for 5-alpha reductase deficiency is anticipated to show significant expansion over the upcoming years. It is projected to attain a valuation of $2.36 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.5%. This forecasted growth can be linked to improvements in gene sequencing technologies, the expansion of newborn and carrier screening programs, a heightened focus on personalized hormone therapy, the establishment of more specialty clinics for rare disorders, and increasing research in genetic endocrinology. Noteworthy trends for the forecast duration include an uptick in the early diagnosis of 5-alpha reductase deficiency, greater public awareness of disorders of sexual development, wider adoption of genetic and hormonal testing, the proliferation of specialized endocrinology and urology care services, and better access to hormone replacement therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report

Which Key Drivers Are Affecting The 5-Alpha Reductase Deficiency Market Development?

The expansion of research and development initiatives within genomics is significantly contributing to the growth of the 5-alpha reductase deficiency market. Genomics encompasses the study of an individual’s entire gene pool (genome), along with how these genes interact with one another and their environment. This scientific discipline is instrumental in diagnosing 5-alpha reductase deficiency by identifying the specific genetic mutations responsible for the condition. Consequently, R&D in genomics will be vital for advancements in discovering and treating the disorder. An illustration of this trend is the increase in U.S. research and development expenditures, which, as reported in February 2025 by the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, rose from $892 billion in 2022 to $940 billion in 2023, indicating a $48 billion surge. Therefore, the increasing volume of research and development activities in genomics is set to drive the 5-alpha reductase deficiency market.

How Are Segments Identified Within The 5-Alpha Reductase Deficiency Market Segment Framework?

The 5-alpha reductase deficiency market covered in this report is segmented –

1) By Diagnosis: Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Other Diagnosis

2) By Treatment: Surgery, Vaginoplasty, Feminizing Genitoplasty, Hormone Replacement Therapy, Other Treatments

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Chromosome Analysis: Karyotyping, Fluorescence In Situ Hybridization (FISH)

2) By Gene Sequencing: Targeted Gene Panels, Whole Exome Sequencing

3) By Hormone Tests: Testosterone Levels, Dihydrotestosterone (DHT) Levels

4) By Imaging Tests: Ultrasound, MRI

5) By Genetic Screening: Carrier Testing, Newborn Screening

6) By Other Diagnosis: Clinical Evaluation, Family History Assessment

What Trends Are Transforming The 5-Alpha Reductase Deficiency Market?

Companies operating within the 5-alpha reductase deficiency market are concentrating on developing technologically advanced products, such as consumer-initiated genetic tests, to enable individuals to obtain personal genetic information directly and privately without needing a healthcare provider’s referral. A consumer-initiated genetic test is a form of genetic assessment that individuals order directly from a laboratory or testing company, typically without the involvement of a healthcare provider, to gain insights into their genetic predispositions, ancestry, or health-related traits. For instance, in July 2023, Quest Diagnostics, a US-based provider of diagnostic information services, launched Genetic Insights, which is a consumer-initiated genetic test. This new offering helps individuals assess their potential risk of developing certain hereditary health conditions. It incorporates advanced technology and comprehensive support, including personalized health reports and access to genetic counseling. By analyzing a saliva sample, Genetic Insights evaluates 36 genes to identify the risk of nearly two dozen hereditary conditions, such as breast and colon cancer, various heart and blood disorders, as well as carrier status for cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. This test is designed to fill the gaps left by existing consumer genetic tests and utilizes cutting-edge next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examines more regions of a person’s genome compared to traditional microarray testing.

Who Are The Companies Competing Within The 5-Alpha Reductase Deficiency Market?

Major companies operating in the 5-alpha reductase deficiency market are F. Hoffmann-La Roche Ltd, Sanofi SA, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Novo Nordisk A S, Regeneron Pharmaceuticals Inc, Roivant Sciences Ltd, Sanofi Genzyme, Shionogi and Co Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, UCB S A, Vertex Pharmaceuticals Incorporated, Cadila Healthcare Limited, Endo International plc

Get The Full 5-Alpha Reductase Deficiency Market Report:

https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report

Which Geographic Region Dominates The 5-Alpha Reductase Deficiency Market?

North America was the largest region in the 5-alpha reductase deficiency market in 2025. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized 5-Alpha Reductase Deficiency Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report

Browse Through More Reports Similar to the Global 5-Alpha Reductase Deficiency Market 2026, By The Business Research Company

Alpha Hydroxy Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/alpha-hydroxy-acid-global-market-report

Combined Pituitary Hormone Deficiencies Market Report 2026

https://www.thebusinessresearchcompany.com/report/combined-pituitary-hormone-deficiencies-global-market-report

Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795